News NGSX 21th May 2026
Guardant stock pops 20%+ on news of FDA approval, investigational study in endometriosis, Helio Genomics liver test, En Carta Diagnostics STD test, One Biosciences single-cell map, Qiagen loves Nvidia
Helio Genomics and Syneos Health Partnership
Helio Genomics has announced a new partnership with Syneos Health to expand the commercialization of its HelioLiver test, a blood-based assay for the early detection of hepatocellular carcinoma. By leveraging Syneos Health’s extensive experience in building and executing commercial programs, Helio aims to accelerate healthcare provider engagement and broad market adoption across the country. The HelioLiver test utilizes artificial intelligence to analyze cell-free DNA methylation patterns, protein biomarkers, and patient demographics. This collaboration builds upon Helio’s existing commercial distribution strategies, which include previous partnerships with Fulgent Genetics and Quest Diagnostics. Financial terms of the newly formed agreement have not been disclosed.
En Carta Diagnostics and AAZ Collaboration
French diagnostic companies En Carta Diagnostics and AAZ have established a codevelopment and commercialization agreement to create rapid, decentralized screening assays for sexually transmitted infections. The collaboration will combine En Carta’s expertise in molecular nucleic acid detection with AAZ’s proficiency in developing rapid self-tests. Within the next three years, the partners aim to deploy new molecular tests across Europe that can screen for chlamydia and gonorrhea in under thirty minutes. These highly accessible tests are being designed specifically for use in primary care facilities, pharmacies, and home testing environments. The companies project that test distribution volumes will reach several million units over a five-year period.
Cyclana Bio Endometriosis Study
Cyclana Bio has received approval from the UK’s National Health Service to launch an observational study aimed at discovering new biomarkers and druggable targets for endometriosis. The Predicting Endometriosis Mechanisms and Populations (PEMP) study plans to enroll 500 patients to collect biopsies and menstrual fluid for the creation of advanced in vitro 3D disease models. By applying genomic analysis and molecular phenotyping to these models, researchers hope to better understand the disease’s underlying biology and complex extracellular matrix dynamics. The ultimate goal is to evaluate whether endometriosis requires a personalized medicine approach or if a singular treatment pathway can be effective. This research initiative is fully supported by a £5 million pre-seed funding round that the Cambridge-based firm closed last October.
Gustave Roussy and One Biosciences Integration
The French cancer institute Gustave Roussy has formed a collaboration with One Biosciences to investigate the use of single-cell technology and artificial intelligence in predicting patient responses to cancer treatments. The partnership will utilize One Biosciences’ AI-driven single-cell profiling platform, OneMap, to analyze anonymized frozen tissue samples across four different cancer indications. Researchers aim to decipher tumor heterogeneity at the single-cell level to better understand unique cell populations and predict potential treatment resistance. Ultimately, the organizations hope to generate rapid, highly individualized, and actionable reports that can be seamlessly integrated into molecular tumor board reviews to guide smarter clinical decisions. This prospective clinical integration directly follows a successful initial feasibility study that demonstrated the AI platform’s ability to process patient data effectively.
Blank Bio Seed Funding and Development
Blank Bio, an artificial intelligence startup based in San Francisco, has successfully secured $7.2 million in seed financing to advance the development and commercialization of its RNA foundation models for precision medicine. The company focuses primarily on utilizing bulk RNA sequencing data to capture comprehensive transcriptomic details, such as splice isoforms, mutations, and overall expression. While initially targeting oncology applications for clinical and pharmaceutical deployment, the firm expects its models to eventually be indication-agnostic. To further enhance its training, Blank Bio has partnered with Pacific Biosciences to generate bulk long-read RNA sequencing data from up to 100 fresh frozen patient tumor samples at the Seattle Children’s Research Institute. Pacific Biosciences is providing significant in-kind support for this project, including its Kinnex library prep kits and Revio sequencing technology. This collaboration will help showcase how high-resolution transcriptomic data can improve biomarker discovery and patient stratification compared to traditional short-read methods. Moving forward, Blank Bio aims to utilize this funding to double down on model training and expand its commercial partnerships. Ultimately, the startup also plans to incorporate diverse data modalities like single-cell, spatial, and multiomics data to unlock an even higher resolution of disease biology.
EpiCypher and NEB Partnership Expansion
EpiCypher and New England Biolabs (NEB) have announced the expansion of their 2022 partnership to further develop and commercialize epigenomics research tools. Building on their initial collaboration involving CUT&RUN library preparation kits, the two companies are now expanding into long-read sequencing applications. This expansion includes the integration of NEB reagents into EpiCypher’s recently launched CUTANA Fiber-seq kit. Furthermore, NEB will begin distributing EpiCypher’s CUTANA portfolio of genomics products in international markets, initially focusing on Germany and the United Kingdom before expanding to additional markets later this year. This strategic alliance aims to combine EpiCypher’s assay development capabilities with NEB’s enzyme expertise to deliver next-generation tools for studying gene regulation and disease biology.
Large GWAS Meta-Analysis Links Blood Metabolites to Common, Rare Genetic Variants
Investigators have utilized data from over 600,000 individuals across the Estonian and UK Biobanks to identify significant associations between blood metabolic traits and both common and rare genetic variants. The massive genome-wide association study meta-analysis successfully mapped 88,127 variant-metabolic trait associations involving 249 different metabolic traits measured via nuclear magnetic resonance (NMR). By employing such a vast sample size, the research team discovered low-frequency variants that had been excluded from previous studies, representing more than 8 percent of their new discoveries. Furthermore, the study provided crucial insights into disease pathways, revealing that targeting branched-chain amino acid (BCAA) catabolism would not actually reduce the risk of type 2 diabetes despite previous clinical assumptions. These findings are now publicly available through the GWAS Catalog to assist other researchers in exploring causal links to human diseases. This study is yet another demonstration that the WGS data from biobanks like the UK Biobank and the Estonian Biobank are the “gift that keeps on giving”, and that layering rich phenotypical data on top of the genetic data in WGS samples provides a rich ground for scientific discovery.
Proposed Law Would Update CLIA With New Provisions for LDT Oversight
Representative Neal Dunn recently introduced the Enhancing CLIA Act of 2026 to the US House of Representatives to modernize the oversight of laboratory-developed tests (LDTs). This proposed legislation seeks to codify that LDTs are professional medical services regulated by the Centers for Medicare and Medicaid Services (CMS) rather than medical devices subject to FDA jurisdiction, directly addressing a 2025 court decision. The bill would mandate CMS to create a comprehensive database to track LDT performance characteristics and establish a centralized system for error reporting. Additionally, it would allow laboratories to submit their tests for voluntary third-party reviews to confirm analytical and clinical validity. The American Clinical Laboratory Association has already expressed its support for this legislative approach, noting it updates regulations without placing burdensome limits on scientific progress or patient access.
This goes in the direction of having more nimble LDTs approved faster, taking the load off the FDA, which as an agency has so much work to do on top of approving LDTs.
Qiagen to Integrate Nvidia Computing, AI Into Bioinformatics Platform
Qiagen announced a new partnership with Nvidia to integrate the Nvidia BioNeMo platform and accelerated computing into its curated digital bioinformatics knowledgebases. This collaboration centers on Qiagen’s Discovery Platform to help biotech and pharmaceutical researchers uncover biomarkers, understand disease biology, and identify promising therapeutic targets. By employing graph-based artificial intelligence, the combined platform will allow researchers to ask natural language questions while maintaining direct links to structured scientific evidence. Qiagen plans to initially roll out pilot programs of this technology to select industry partners before expanding its availability to the broader market. Ultimately, this integration aims to significantly support and streamline multi-step drug discovery workflows across the biological sciences.
Qiagen has a long history of bringing in software to complement the instruments and assays they sell. About a couple of decades ago, they acquired the Danish software platform CLC, which is still front and center in their software support for NGS and Multiomics.
Personalis Nabs Medicare Coverage of MRD Test for Breast Cancer Pre-Surgical Treatment Monitoring
Personalis announced that the US Centers for Medicare and Medicaid Services has expanded its coverage for the company’s NeXT Personal minimal residual disease (MRD) test. The updated coverage now includes the monitoring of neoadjuvant treatment responses in patients diagnosed with stages II to III triple-negative or HER2-positive breast cancer. This marks the fourth Medicare coverage decision for the company’s whole-genome sequencing-based, tumor-informed assay, bolstered by evidence from the PREDICT-DNA clinical study. Personalis CEO Chris Hall highlighted that this milestone firmly moves their ultrasensitive MRD technology into the realm of active treatment management. Following the announcement, shares of Personalis stock saw a nearly 9 percent increase in early morning trading on the Nasdaq.
Guardant Health Upgraded CDx Secures FDA Approval
Guardant Health recently secured FDA approval for its upgraded Guardant360 Liquid CDx test, which analyzes a genomic footprint 100-fold larger than its predecessor by collecting both genomic and epigenomic information from a single blood draw. This significant regulatory milestone perfectly aligns with the predictions made in our GH JPM26 slide deck review, where we explicitly identified the “Guardant360 Liquid FDA approval and launch” as a primary upcoming catalyst for the company in 2026. The newly approved test absorbs seven previously approved CDx indications, including targeted therapies for advanced breast cancer and multiple therapies for non-small cell lung cancer. Financial analysts predict this approval could accelerate the assay’s Advanced Diagnostic Laboratory Test pricing timeline, potentially driving additional upside beyond the company’s previously stated 2026 guidance. Following this news, Guardant Health’s stock experienced a 21 percent boost in the past 5 trading days, further validating your earlier analysis of the company’s strong market momentum.
Rhymes with Haystack - Guardant Health JPM26
Guardant Health’s JP Morgan Healthcare 2026 presentation highlighted a highly successful trajectory for the company, marked by impressive total revenue growth that reached an estimated $981 million in 2025. The company operates a comprehensive oncology platform that covers the entire patient journey, from early screening with Guardant SHIELD to profiling with Guardant360 and monitoring via Guardant REVEAL. A major driver of this continued innovation is InfinityAI, an artificial intelligence tool leveraging over 400,000 epigenetic profiles to provide clinical insights and power a smart app that helps physicians navigate integrated patient journeys. In the minimal residual disease (MRD) space, Guardant is preparing to launch REVEAL ULTRA in 2026, which promises a best-in-class limit of detection below one part per million to identify cancerous DNA with exceptional sensitivity. The company’s ambitious early bet on multi-cancer screening is also paying off, with the SHIELD assay showing massive volume growth from 6,000 to 38,000 quarterly tests within a single year. Looking beyond oncology, Guardant envisions expanding the SHIELD platform to eventually detect neurodegenerative, cardiovascular, and autoimmune diseases. Financially, the company boasts a strong balance sheet with $1.3 billion in cash and projects to reach free cash flow breakeven by the fourth quarter of 2027.
